Trade Harrow Health, Inc. - HROW CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.12
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02224 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02224%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00001 %($0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00001%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02224 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00001 %
  ($0.00)

Key Stats

• Prev. Close: 28.71
• Open: 28.22
• 1-Year Change: -28.5%
• Day's Range: 27.06 - 28.22

Trade Harrow Health, Inc. - HROW

About Harrow Health Inc

Harrow Health, Inc. is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. The Company holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The Company also owns royalty rights in four clinical stage drug candidates, which are being developed by Surface Ophthalmics and Melt Pharmaceuticals.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Harrow Health Inc revenues increased 48% to $72.5M. Net loss applicable to common stockholders increased from $3.4M to $18.5M. Revenues reflect Product sales, net increase of 43% to $69.1M, Other revenues increase from $392K to $3.4M. Higher net loss reflects Investment losses from Eton Pharmaceutic decrease from $3.3M (income) to $10.1M (expense), Selling.

Equity composition

Common stock, $.001 Par, 02/12, 50M auth., 1,991,508 issd. Insiders own approx. 27.50%. 02/12, 1-for-8 Reverse split. 1-for-5 reverse stock split.